The following article features coverage from the Society of Gynecologic Oncology’s 50th Annual Meeting on Women’s Cancer. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

Results of this retrospective study showed that adjuvant chemoradiation (CRT) did not significantly improve overall survival (OS) compared with adjuvant radiation therapy (RT) alone in women with squamous cell carcinoma of the vulva. These findings were presented at the Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer.

In a multi-institutional retrospective cohort study, 57 patients received adjuvant therapy for stage IB or higher squamous cell carcinoma of the vulva from 1995 to 2015. Of these patients, 47% and 53% received radiation therapy alone and chemoradiation, respectively. The median age of the women in each of these groups differed significantly (ie, 63 years [CRT] vs 67 years [RT], P <.05). However, no significant clinicopathologic differences were observed in body mass index, disease stage, nodal status, or tumor size when the 2 groups were compared. 

Related Articles

Importantly, after a median follow-up of 16.7 months a comparison of OS in the 2 groups did not reveal a significant difference (P =.77), and no significant difference in OS was observed after controlling for patient age (P =.59). While a trend for longer progression-free survival (PFS) was observed in the group receiving CRT (ie, 57.3 months vs 21.7 months; P =.08), this difference became less pronounced after controlling for patient age (P =.20).

Read more of Cancer Therapy Advisor‘s coverage of SGO’s annual meeting by visiting the conference page.

Reference

  1. Castellano T, Brinkman D, Ding K, et al. Outcomes associated with chemoradiation versus radiation alone in squamous cell carcinoma of the vulva. Presented at: Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer; Honolulu, Hawaii; March 16-19, 2019. Abstract 51.